Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection

Trial Profile

COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMBI-AD
  • Sponsors GlaxoSmithKline; Novare Pharmaceuticals; Novartis Pharma A.G.
  • Most Recent Events

    • 04 Jun 2019 Results exploring the association between baseline disease characteristics and RFS to identify pt subgroups likely to benefit from adjuvant treatment, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Mar 2019 Results published in the Lancet Oncology
    • 01 Nov 2018 According to a Novartis media release, based on the data from this trial,Novartis receives Health Canada approval for the combination therapy of Tafinlar(dabrafenib) plus Mekinist(trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top